Phase III clinical study of Cinda Bio-Innovative Oncology Drug Damerschu ® (SindyLi Monoantigen) completes first patient administration

today (January 17), Cinda Bio
Pharmaceutical(http://(Hong Kong Stock Exchange Code: 01801) announced that the Innovative OncologyDrug(http://Dabershu ® (Recombinant Whole Human Source Anti-PD-1 Monoclonal Antibodies, English Trademark: Tyvyt®, Chemical Common Name: Cindy Li Mono-injection) combined with Capetabin and Osali platinum first-line treatment of non-reprecision of late-localized, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma Phase III clinical study (ORIENT-16) completed the first patient administrationabout Dabershu ® (Sindili mono-injection)Dabershu® (Sindy Li mono-injection) is an international-quality innovative biopharmaceutical developed by Cinda Biopharma and Lilly Pharmaceuticals in China, with global intellectual property rightsDaboshu ® (Sindyli monoantigen) is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to pD-1 molecules on the surface of T cells, thus blocking the PD-1/programmed death receptor ligand-1, PD-L1 pathway that causes tumor immunity to tumor resistance to tumor reactivationDaboshu ® (Sindili mono-resistant injection) is an internationally qualified Chinese innovative PD-1 inhibitorthe ORIENT-16 studyORIENT-16 study is a randomized, controlled, double-blind, multicenter PHASE III study, which assesses the effectiveness and safety of endostage, recurrent or metastatic gastroandaand esophageal and gastroesophageal adenomas that cannot be removed from the daboschu® (Sindili monoantigen) or placebo-combined capertatandand and Oshali platinum first-line therapy for non-restructable late-stage, recurrent or metastatic gastroesophageal and gastroesophageal junction adenocarcinomaThe ORIENT-16 study was based on a Phase Ib study that evaluated the combination of Dapershu ® (Sindili monoantigen) chemotherapy for patients with stomach cancer